US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

35.24

-0.2499-0.70%

Post-market: 35.250.0137+0.04%16:10 EDT

Volume:732

Turnover:25.84K

Market Cap:16.56M

PE:- -

High:35.25

Open:35.25

Low:35.24

Close:35.49

52wk High:37.90

52wk Low:28.87

Shares:469.95K

Float Shares:469.95K

Volume Ratio:1.05

T/O Rate:0.16%

Dividend:0.41

Dividend Rate:1.16%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

MediciNova to Participate in Two Investor Conferences in September

Press Release: Waterdrop Inc. Announces Second Quarter 2026 Unaudited Financial Results and a Cash Dividend

Novartis India Hits Record High on Retina Drugs Distribution Deal, Pfizer Brand Acquisition

Upstream Bio presents results from VALIANT trial at ERS Congress

Stocks to Watch: Amgen, Nike, Bloom Energy

Novartis Stock (NVS) Sinks on Another Setback, Muscle-Wasting Disorder Drug Disappoints

Pharmaceutical Giant's Shares Plunge Nearly 10% Following Triple Clinical Trial Setbacks

Novartis Might Need More Deals to Deliver Growth Ambitions

Why the Dow is Being Dragged Down by a Swiss Company's Bad News

AlzeCure Pharma to Present at Aktiedagen Event in Stockholm

Novartis's Latest Trial Setback Sinks Stock

Novartis Genetic Muscle Disorder Drug Fails Phase 3 Trial; Shares Drop Pre-Bell

MT Newswires Live

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday

Benzinga Earnings

Novartis's Latest Trial Failure is Second Pipeline Setback in a Row

2026 Health and Life Sciences Conference Concludes Successfully in Guangzhou, Driving Bay Area Synergy and Global Partnerships

China Securities Reports Medical Device Sector Sustains Earnings Improvement While Medical Services Revenue Grows Steadily

European Equities Remain Flat as Energy Gains Offset by Pharma Slump

Novartis AG Falls Monday, Underperforms Market

Citi says Novartis news increases likelihood Crispr prioritizes next-gen CTX321

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/MEDX/news?page=14"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"MEDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","market":"US","secType":"STK","nameCN":"HORIZON KINETICS MEDICAL ETF","latestPrice":35.2363,"timestamp":1789761600000,"preClose":35.4862,"halted":0,"volume":732,"hourTrading":{"tag":"盘后","latestPrice":35.25,"preClose":35.2363,"latestTime":"16:10 EDT","volume":6,"amount":211.4178,"timestamp":1789762204085,"change":0.0137,"changeRate":0.000389,"amplitude":0},"delay":0,"changeRate":-0.007042174140933566,"floatShares":469946,"shares":469946,"eps":0,"marketStatus":"Market Closed","change":-0.2499,"latestTime":"09-18 16:00:00 EDT","open":35.25,"high":35.25,"low":35.2363,"amount":25837,"amplitude":0.000386,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":35.4862,"sharesOutstanding":569946,"nav":35.46,"aum":16664285.16,"dividendRate":0.011607,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.25,"preClose":35.2363,"latestTime":"16:10 EDT","volume":6,"amount":211.4178,"timestamp":1789762204085,"change":0.0137,"changeRate":0.000389,"amplitude":0},"volumeRatio":1.0469104706622006},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","floatShares":469946,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.0469104706622006,"shares":469946,"dividePrice":0.409,"high":35.25,"amplitude":0.000386,"preClose":35.4862,"low":35.2363,"week52Low":28.8652,"pbRate":"--","week52High":37.9,"institutionHeld":0,"latestPrice":35.2363,"eps":0,"divideRate":0.011607,"volume":732,"delay":0,"ttmEps":0,"open":35.25,"prevYearClose":33.2024,"prevWeekClose":34.9572,"prevMonthClose":36.417,"prevQuarterClose":36.7138,"fiveDayClose":34.9572,"twentyDayClose":37.0138,"sixtyDayClose":34.8443},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MEDX\",params:#limit:5,,,undefined,":[{"date":"2025-12-23","symbol":"MEDX","amount":0.4088,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-24"},{"date":"2024-12-24","symbol":"MEDX","amount":0.502335,"announcedDate":"2024-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-24","defaultRemindTime":1735050600000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-24","currency":"USD","dateTimestamp":1735016400000,"payDate":"2024-12-26"},{"date":"2023-12-27","symbol":"MEDX","amount":1.379798,"announcedDate":"2023-12-26","type":"dividend","market":"US","newRecordDate":"2023-12-28","defaultRemindTime":1703687400000,"name":"HORIZON KINETICS MEDICAL ETF","recordDate":"2023-12-29","payableDate":"2023-12-28","currency":"USD","dateTimestamp":1703653200000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MEDX\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-27","recordDate":"2023-12-28","paymentDate":"2023-12-29","value":1.379798,"currency":"USD"},{"executeDate":"2024-12-24","recordDate":"2024-12-24","paymentDate":"2024-12-26","value":0.502335,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-24","value":0.4088,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MEDX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MEDX\",pageSize:20,pageCount:14,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665601324","title":"MediciNova to Participate in Two Investor Conferences in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2665601324","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665601324?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":"LA JOLLA, Calif., Sept.  08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchang","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357430/7767/en/medicinova-to-participate-in-two-investor-conferences-in-september.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1732799900.SGD","LU0098860793.USD","LU0210528500.USD","LU0912757837.SGD","LU2347655156.SGD","BK4139","LU0390134368.USD","BK4585","LU1074936037.SGD","LU0528227936.USD","BK4516","IE00BKVL7J92.USD","LU2089284900.SGD","LU2028103732.USD","LU0971096721.USD","LU2487616109.SGD","LU0557290698.USD","LU1548497426.USD","MEDX","LU1064131342.USD","IDNA","LU1989772840.SGD","LU1791710582.SGD","LU1720051017.SGD","BK4127","BK4504","LU2089283258.USD","LU0267386448.USD","LU1720051108.HKD","BK4588","KBWB","LU0006306889.USD","LU2264538146.SGD","HYLG","LU1989772923.USD","IE00BZ1G4Q59.USD","BK4534","IAI","LU0053666078.USD","MNOV","LU1791710400.SGD","NVIB","LU2133065610.SGD","LU0106831901.USD","LU2111349929.HKD","GDOC","BMED","LU0234570918.USD","IE00B3S45H60.SGD","LU0795875169.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321351","title":"Press Release: Waterdrop Inc. Announces Second Quarter 2026 Unaudited Financial Results and a Cash Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321351","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321351?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":"BEIJING, Sept. 8, 2026 /PRNewswire/ -- Waterdrop Inc.  , a leading technology platform dedicated to insurance and healthcare services with a positive social impact, today announced its unaudited financial results for the three and six months ended June 30, 2026 and a cash dividend.Financial and Operational Highlights for the Second Quarter of 2026-- Strong Core Business Growth: Net operating revenue for the second quarter. rose to RMB1,448.2 million , representing a robust. year-over-year increase of 72.8%. Insurance-related income for the. quarter reached RMB1,333.2 million , up 80.5% from the. -- Improved Operating Performance: In the second quarter of 2026, operating","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","CHAT","AGIX","BK4539","HYLG","WDH","IDNA","BK4509","GDOC","MEDX","VTHR","BK4173","ARTY","QTOC","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326663","title":"Novartis India Hits Record High on Retina Drugs Distribution Deal, Pfizer Brand Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326663","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665326663?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:12","pubTimestamp":1788858752,"startTime":"0","endTime":"0","summary":"BUZZ-Novartis India hits record high on retina drugs distribution deal, Pfizer brand acquisition** Shares of Novartis IndiaNOIN.BOjump as much as 12.9% to a record high of 1,850.95 rupees** NOIN enters into an exclusive promotion and distribution agreement with Novartis Healthcare to market its retina portfolio in India** Under the deal, NOIN will exclusively distribute Accentrix and Pagenax in India, marking its entry into ophthalmology, and will pay NHPL an upfront fee of 100 million rupees ** On Monday, Novartis India said that it will acquire the Minipress brand and related IP from PfizerPFE.Nfor about 12.5 billion rupees** Pfizer IndiaPFIZ.NSwill stop selling Minipress XL and receive $13.9 million from the parent; the drug is used to treat hypertension and BPH-related urinary symptoms** YTD, NOIN up ~137%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4N4500KV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","BK4007","LU0208291251.USD","IE00BJJMRZ35.SGD","NVS","BK4585","BK4532","IE0002141913.USD","BK4578","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0211331839.USD","MEDX","PPH","IE0009355771.USD","LU0070302665.USD","LU0320765489.SGD","IE00B4R5TH58.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326159","title":"Upstream Bio presents results from VALIANT trial at ERS Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665326159?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:10","pubTimestamp":1788858619,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) presented results from the Phase 2 VALIANT clinical trial evaluating the safety and efficacy of verekitug in adults with severe ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bio-presents-results-from-valiant-trial-at-ers-congress-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bio-presents-results-from-valiant-trial-at-ers-congress-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB","MEDX","GDOC","HYLG","NVIB","BK4139","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665342326","title":"Stocks to Watch: Amgen, Nike, Bloom Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665342326","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665342326?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:07","pubTimestamp":1788858420,"startTime":"0","endTime":"0","summary":"Amgen : Shares of the biotechnology company, a major contributor to the Dow, shed more than 5% premarket after the Swiss drugmaker Novartis  said an experimental medicine failed to reduce cardiovascular risk in a late-stage clinical trial. Amgen and Eli Lilly  are working on rival treatments. Novartis shares tumbled 10% in Europe, while Eli Lilly shares ticked down.Bloom Energy : The fuel-cell maker is among the companies that will join the S&P 500 later this month, S&P Dow Jones Indices announced late Friday, sending its shares 4% higher premarket. Meanwhile, Nike  will be deleted from the S&P 100. Its shares edged lower premarket.Coinbase Global , Robinhood Markets , Strategy : Shares of companies tied to cryptocurrencies retreated in premarket trading as bitcoin's price slipped more than 1% to trade below $78,500.GameStop  is set to report earnings after markets close.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOOY","LU2360107671.USD","CRPT","BK4577","LU2242652126.USD","BLCK","LU0289739699.SGD","BEZ","COIA","SG9999001440.SGD","LU1861559042.SGD","LU0208291251.USD","BITQ","BK4076","BK4599","MSTY","LU0823414478.USD","LU0070302665.USD","IE00BFTCPJ56.SGD","DAPP","OWNB","BK4551","COII","LU0786609619.USD","SMOG","COIG","LU1064131342.USD","LU1861558580.USD","LU0058720904.USD","IMST","LU0310800379.SGD","MTYY","3SMI.UK","BEG","09799","07799","LU0476273544.USD","IE00BFXG0V08.USD","MSTW","LU2543165471.USD","MSTK","LU0211331839.USD","LU0052756011.USD","LU0792757196.USD","LU0708994859.HKD","BK4533","LU0823414551.USD","ROBN","FIAT","3LMI.UK","BK4007","GME","BK4127","BK4541","HOOI","IE0009355771.USD","SIMS","BK4600","LU1861220207.SGD","MSDD","HOOC","LU1988902786.USD","07311","07399","MSTR","CNRG","BK4023","SMI3.UK","MSST","LU2089984988.USD","BK4182","09311","BEX","TBXU","GMEU","07711","COIO","BK4558","CTEC","LU0029864427.USD","IAI","WATS","APED","BK4547","LU0128525689.USD","LU0310800965.SGD","HOII","BK4581","HOOX","BPAY","MSTC","LU1023059063.AUD","LU2098885051.SGD","SMST","MSTY.UK","LU1861217088.USD","BEC","COYY","PBE","LU2357125470.USD","MSOO","BK4561","LU0128525929.USD","LU2294711713.HKD","LU2249611893.SGD","LU0109394709.USD","CONL","MSTP","VCLN","BK4596","HOOD","MSTZ","BK4539","09711","FRNW","IE0002141913.USD","BK4112","IE00B4R5TH58.HKD","LU1571399168.USD","COIX","LU1642822529.SGD","LU2264538146.SGD","COIW","NKE","EGGY","LU2112291526.USD","CONI","AMGN","04332","IE00BJT1NW94.SGD","LU1267930227.SGD","NVS","BK4532","BIB","BK4595","HOYY","PPH","CONY","BK4566","HOOG","LMI3.UK","BK4534","LU1815336760.USD","STYL","VTWG","LU0957808578.USD","HOOZ","LU1983299246.USD","LU1057294990.SGD","BBH","BK4535","LU0889565916.HKD","BK4516","LU0889566641.SGD","ZAP","LU0868494617.USD","MSII","COIN","FDIG","IBAT","LU0122379950.USD","LU0444971666.USD","LU0320765489.SGD","IBB","UPGR","WNTR","FINX","LU1267930813.SGD","LU2506951792.HKD","BE","BK4554","BK4578","LU0823411888.USD","BK4588","LU2468319806.SGD","HODU","MEDX","IBBQ","BKCH","GMEC","IE00B2B36J28.USD","MST","IE0009354923.USD","IE00BYQQ9H92.USD","MSTX","HOOW","ICLN","BK4585","ICOI","LU0320765992.SGD","IGME","LU0444973449.USD","IE00BJJMRZ35.SGD","CONX","09399","BK4146","GMEY","LU1303367103.USD","LU2242646821.SGD","PJP","IBLC","LU1061106388.HKD","LU1267930573.SGD","MSTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665261713","title":"Novartis Stock (NVS) Sinks on Another Setback, Muscle-Wasting Disorder Drug Disappoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2665261713","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665261713?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:03","pubTimestamp":1788858204,"startTime":"0","endTime":"0","summary":"Novartis ($NVS) stock plunged about 13% in Tuesday’s pre-market trading as the Swiss drugmaker’s experimental drug, del-desiran, for a muscle-wasti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/novartis-stock-nvs-sinks-on-another-setback-muscle-wasting-disorder-drug-disappoints?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/novartis-stock-nvs-sinks-on-another-setback-muscle-wasting-disorder-drug-disappoints?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009355771.USD","LU0208291251.USD","LU0320765489.SGD","IE0002141913.USD","BK4007","NVS","BK4578","LU0211331839.USD","BK4532","BK4588","IE00BFTCPJ56.SGD","LU0070302665.USD","PPH","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","MEDX","IE00B4R5TH58.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125754221","title":"Pharmaceutical Giant's Shares Plunge Nearly 10% Following Triple Clinical Trial Setbacks","url":"https://stock-news.laohu8.com/highlight/detail?id=1125754221","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125754221?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:00","pubTimestamp":1788858037,"startTime":"0","endTime":"0","summary":"Swiss pharmaceutical heavyweight Novartis faced a turbulent trading session on Tuesday as its shares tumbled sharply following the disclosure that its experimental drug for muscular dystrophy,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IBBQ","LU0320765489.SGD","IE00BJT1NW94.SGD","LU0211331839.USD","IE0009355771.USD","BK4532","IE00BFTCPJ56.SGD","PSYK","IE0002141913.USD","IBBJ","LU0208291251.USD","IE00BJJMRZ35.SGD","LU0070302665.USD","MDTX","BK4007","BK4578","PPH","BK4585","IE00B2B36J28.USD","MEDX","IE00B4R5TH58.HKD","BK4588","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323400","title":"Novartis Might Need More Deals to Deliver Growth Ambitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323400","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323400?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:17","pubTimestamp":1788855420,"startTime":"0","endTime":"0","summary":"0817 GMT - Novartis's latest clinical-trial failure suggests the company might need more dealmaking to deliver on its ambition for steady growth beyond 2030, Jefferies analysts say in a research note. The Swiss drugmaker maintained its 2025-30 sales guidance as it said its neuromuscular drug del-desiran missed the main goal in a late-stage study. However, no comment was provided on the ambition to grow by mid-single percentage digits beyond 2030, the analysts say. Even with the recent success of a new multiple-sclerosis pill, it will be challenging to get confidence on the company's growth for the 2030s without del-desiran and del-brax, two drugs Novartis acquired from Avidity Biosciences, Jefferies says. As a result, dealmaking will likely remain part of Novartis's story, the analysts add. Shares fall 10%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","MEDX","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0070302665.USD","IE0002141913.USD","LU0320765489.SGD","IE00B4R5TH58.HKD","LU0208291251.USD","IE00BJT1NW94.SGD","PPH","BK4585","BK4578","BK4532","BK4588","LU0211331839.USD","NVS","BK4007","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665532340","title":"Why the Dow is Being Dragged Down by a Swiss Company's Bad News","url":"https://stock-news.laohu8.com/highlight/detail?id=2665532340","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665532340?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:15","pubTimestamp":1788855300,"startTime":"0","endTime":"0","summary":"Bad news from Swiss pharmaceutical giant Novartis was weighing on the Dow on Tuesday.Investors returning from the Labor Day break could be forgiven for wondering if their eyes were deceiving them, but","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4139","BK4566","LU0058720904.USD","BK4532","IE00BFTCPJ56.SGD","LU2112291526.USD","AMGN","BK4588","BK4585","LU1983299246.USD","BBH","LU0109394709.USD","PPH","PJP","LU2468319806.SGD","IE0002141913.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","TBXU","LU0070302665.USD","LU0868494617.USD","BK4534","NAMS","MEDX","PBE","LU2242652126.USD","IBB","LU0208291251.USD","LU0320765489.SGD","LU1057294990.SGD","BK4007","IBBQ","IE00B4R5TH58.HKD","BK4581","LU2089984988.USD","BK4578","LU0122379950.USD","IE0009355771.USD","BK4533","LU0889565916.HKD","LU0320765992.SGD","LU0211331839.USD","BIB","SG9999001440.SGD","NVS","LU0289739699.SGD","IE00B2B36J28.USD","LU1061106388.HKD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323952","title":"AlzeCure Pharma to Present at Aktiedagen Event in Stockholm","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323952","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323952?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:03","pubTimestamp":1788854584,"startTime":"0","endTime":"0","summary":"AlzeCure Pharma to present at Aktiedagen event in StockholmAlzeCure will present at Aktiespararna’s Aktiedagen in Stockholm on Sept. 15.CEO Martin Jnsson is scheduled to speak at 16:25 CEST at Birger ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL83QQ0r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1548497426.USD","LU2168564065.EUR","IHE","LU1917777945.USD","LU0174119429.USD","GB00BDT5M118.USD","SG9999014906.USD","LU0238689110.USD","LU2357305700.SGD","LU0471298777.SGD","LLYZ","LU2237443895.HKD","LU2552382132.HKD","LU2023250330.USD","SG9999014880.SGD","LU1983299246.USD","LU1720051108.HKD","SG9999015986.USD","JDOC","LU1232071149.USD","LU2028103732.USD","IE00BJJMRZ35.SGD","BK4588","LU1093756168.USD","LU2213496289.HKD","LU1868836591.USD","LU1720051017.SGD","IE00BK4W5M84.HKD","IE00BJJMRY28.SGD","LU0354030438.USD","LU1366192091.USD","LU2602419157.SGD","IYH","LU0256863902.USD","LU0158827781.USD","SG9999018865.SGD","TMED","PJP","LU2456880835.USD","LU2896262040.SGD","LU2746668461.USD","LU0320765059.SGD","LU0323591593.USD","LU2462157665.USD","LU0964807845.USD","LU1814569148.SGD","LU0640476718.USD","AGNG","LLII","LU0823416689.USD","LU2168564495.EUR","LU2237443622.USD","LU0158827948.USD","LU0471298694.HKD","SG9999017495.SGD","LU0683600562.USD","LU1868837136.USD","LU0198837287.USD","LU2271345857.HKD","LU2361044865.SGD","LU2023250504.SGD","LU1989771016.USD","SGXZ51526630.SGD","WDNA","LU2089283258.USD","SG9999018857.SGD","LU2237443465.HKD","LU1323610961.USD","LU0345770993.USD","LU2462591350.SGD","PPH","LU0058720904.USD","LU1127390331.HKD","SGXZ57979304.SGD","SG9999001176.USD","LU0203202063.USD","IE00B1XK9C88.USD","LU1551013342.USD","LU1093756325.SGD","LU0097036916.USD","LU2552382215.SGD","LU1035775433.USD","LU0320765992.SGD","LU2265009873.SGD","LU2324357040.USD","LU2491049909.HKD","HRTS","LU0820561909.HKD","LU1145028129.USD","CURE","LU2168564222.USD","LU2264538146.SGD","LU2491050071.SGD","SG9999015945.SGD","LU0133085943.USD","LU0456855351.SGD","LU2168564149.EUR","LU0432979614.USD","LU1057294990.SGD","LU1023059063.AUD","LU0417517546.SGD","RXL","IE00BFSS7M15.SGD","LU0234572021.USD","LU1061106388.HKD","IE00B1BXHZ80.USD","LU0266013472.USD","LU1291159041.SGD","LU0316494557.USD","LU2468319806.SGD","LU2237443549.SGD","LU0256863811.USD","LU1804176565.USD","LU2087625088.SGD","LU1267930730.SGD","LU2237443382.USD","LU0353189763.USD","LU2236285917.USD","SG9999015978.USD","LU2471134523.USD","THNR","IE00B775H168.HKD","IE00BKPKM429.USD","BK4585","SGXZ99366536.SGD","TRUH","IE00BK4W5L77.USD","LU2750360997.AUD","IE00B7KXQ091.USD","IE0009355771.USD","IXJ","LU0466842654.USD","LU0006306889.USD","LU0943347566.SGD","LLY","LLYX","ILDR","LU1868836757.USD","LU1979441026.SGD","SGXZ81514606.USD","SG9999001176.SGD","IE0004445015.USD","IE0004445239.USD","LU0122379950.USD","LU2089984988.USD","BK4599","VHT","LU0079474960.USD","LU2552382058.USD","LU1069344957.HKD","BK4581","LU2360106947.USD","LU0882574139.USD","LU0820561818.USD","LU2756315664.SGD","SG9999015952.SGD","LU0345770308.USD","LU1868837300.USD","LU2211815571.USD","ELIL","LU2746668974.SGD","LU0708995401.HKD","IE00B2B36J28.USD","LU0203201768.USD","LU2361044949.HKD","LU2361045086.USD","LU2461242641.AUD","LU0094547139.USD","LU1623119135.USD","LU2417539215.USD","MEDX","LU0823434740.USD","LU0225283273.USD","MHIP","BK4534","LU0096364046.USD","LU2750360641.GBP","LU0787776722.HKD","LU0689472784.USD","LU2471134952.CNY","IE00B4R5TH58.HKD","LU0109391861.USD","LU1868836914.USD","IE00BFTCPJ56.SGD","LU1629891620.HKD","LU2491050154.USD","SGXZ31699556.SGD","LU0353189680.USD","OZEM","LU1064131342.USD","BK4007","LU2471134879.HKD","LU0889565916.HKD","ELIS","GDOC","IE00BN29S564.USD","LU0882574055.USD","IE00B4JS1V06.HKD","LU0210536198.USD","IE00BJT1NW94.SGD","LU1280957306.USD","LU0820562030.AUD","IE0005OL40V9.USD","LU2237438978.USD","CANC","IE0002141913.USD","LU2023251221.USD","LU2063271972.USD","LU2106854487.HKD","LU0289739699.SGD","LU0109394709.USD","LU0061475181.USD","FHLC","LU1988902786.USD","BK4516","LU0823434583.USD","LU2112291526.USD","LU0385154629.USD","BK4533","XLV","IE00BJJMRX11.SGD","LU2089284900.SGD","LU1551013425.SGD","IE0001KFT4U8.USD","SG9999013999.USD","LU2237443978.SGD","SG9999014914.USD","IE00BWXC8680.SGD","LU0672654240.SGD","LU2168563687.JPY","LU2111349929.HKD","LU0786609619.USD","SG9999014898.SGD","LU1712237335.SGD","LU0354030511.USD","LU0106261372.USD","MEDI","LU2108987350.USD","LU2756315318.SGD","IE00BJLML261.HKD","LU0114720955.EUR","LU1974910355.USD","LU1691799644.USD","FTXH","LU2471134796.USD","IE00BFSS8Q28.SGD","IE00BKDWB100.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323985","title":"Novartis's Latest Trial Setback Sinks Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323985","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323985?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:01","pubTimestamp":1788854460,"startTime":"0","endTime":"0","summary":"Novartis shares plunged after the Swiss drugmaker said an experimental neuromuscular medicine missed the primary goal in a late-stage clinical trial, the latest blow to its efforts to find new growth ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0320765489.SGD","PPH","IE00BJT1NW94.SGD","LU0070302665.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4588","IE00B2B36J28.USD","BK4578","LU0208291251.USD","MEDX","BK4532","IE00B4R5TH58.HKD","BK4585","IE00BFTCPJ56.SGD","LU0211331839.USD","IE0009355771.USD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323534","title":"Novartis Genetic Muscle Disorder Drug Fails Phase 3 Trial; Shares Drop Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323534","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323534?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:58","pubTimestamp":1788854332,"startTime":"0","endTime":"0","summary":"Novartis  said Tuesday its phase 3 Harbor study evaluating delpacibart etedesiran in patients with myotonic dystrophy type 1 failed to meet its primary endpoint of video hand opening time.The drug candidate for the genetic muscular disorder displayed signs of clinical activity for its secondary endpoints measuring muscle strength, daily living activities, and mobility during the trial, the company said.The company is analyzing the full dataset to decide future development plans while maintaining its five-year annual sales growth target of 5% to 6% through 2030, Novartis said.Shares of the company were down by more than 13% in Tuesday premarket activity.Price: 138.80, Change: -21.19, Percent Change: -13.24","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0211331839.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4578","BK4588","BK4532","BK4585","IE00B2B36J28.USD","IE0009355771.USD","LU0320765489.SGD","MEDX","LU0070302665.USD","BK4007","IE0002141913.USD","IE00BFTCPJ56.SGD","NVS","IE00B4R5TH58.HKD","PPH","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665157325","title":"Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665157325","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665157325?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:30","pubTimestamp":1788852600,"startTime":"0","endTime":"0","summary":"– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV1)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357341/0/en/upstream-bio-presents-results-from-the-phase-2-valiant-trial-of-verekitug-for-the-treatment-of-severe-asthma-in-oral-presentation-at-ers-congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","TSDD","TSII","TSLQ","TLA","09766","TSLY","TSLP","CRSH","TSLR","GDOC","TSLW","TESC","TSLG","TSLI","TSL","07366","TSLT","TSLS","TSYY","TEST","NVIB","TSLZ","07766","TESL","ELOL","MEDX","TSLL","09366","TSLO","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665402063","title":"United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2665402063","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665402063?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:11","pubTimestamp":1788851511,"startTime":"0","endTime":"0","summary":"Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/long-ideas/26/09/61650635/united-natural-foods-abm-industries-and-3-stocks-to-watch-heading-into-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0320765059.SGD","PPH","UNFI","VGFPF","ABM","BK4568","GXDW","BK4007","IE00B4R5TH58.HKD","BK4585","BK4578","LU0320765489.SGD","IE0009354923.USD","FEBU","BK4532","IE00B2B36J28.USD","VOTE","LU0211331839.USD","BK4082","IE0009355771.USD","LU0070302665.USD","LU0672654240.SGD","LU0708995401.HKD","BK4120","BK4113","FXG","IE00BFTCPJ56.SGD","LU1878469433.USD","IE00BJJMRZ35.SGD","CASY","LU0109391861.USD","MEDX","NVS","IE00BJT1NW94.SGD","DECU","PMDE","JOYT","LU0208291251.USD","LU1267930730.SGD","CODX","BK4102","RGLO","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665034034","title":"Novartis's Latest Trial Failure is Second Pipeline Setback in a Row","url":"https://stock-news.laohu8.com/highlight/detail?id=2665034034","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665034034?lang=en_us&edition=fundamental","pubTime":"2026-09-08 14:46","pubTimestamp":1788849960,"startTime":"0","endTime":"0","summary":"0646 GMT - Novartis just suffered its second major pipeline setback in the past week after a drug candidate it acquired through its recent $12 billion Avidity Biosciences deal failed in a late-stage study, Vontobel's Stefan Schneider says in a research note. News that experimental drug del-desiran missed the goal in a trial for neuromuscular disease myotonic dystrophy type 1 comes after the Swiss pharmaceutical company last week reported disappointing results for cardiovascular medicine pelacarsen. Vontobel had forecast annual peak sales from del-desiran at $3 billion, with a 50% chance of reaching them, and now removes this forecast from its model. As a result, Vontobel cuts its target price on Novartis stock to 125 Swiss francs from 128 francs. Novartis shares closed at 125.46 francs on Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS","IE0009355771.USD","IE0002141913.USD","MEDX","IE00BJT1NW94.SGD","LU0320765489.SGD","BK4007","BK4588","IE00BFTCPJ56.SGD","LU0070302665.USD","LU0211331839.USD","BK4585","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU0208291251.USD","PPH","BK4578","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103095218","title":"2026 Health and Life Sciences Conference Concludes Successfully in Guangzhou, Driving Bay Area Synergy and Global Partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=1103095218","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103095218?lang=en_us&edition=fundamental","pubTime":"2026-09-08 12:01","pubTimestamp":1788840064,"startTime":"0","endTime":"0","summary":"On September 4, 2026, the \"2026 Health and Life Sciences Conference,\" themed \"Focusing on Bay Area Synergy and Expanding International Cooperation,\" was successfully held in Guangzhou. The event was...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MVP","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106413707","title":"China Securities Reports Medical Device Sector Sustains Earnings Improvement While Medical Services Revenue Grows Steadily","url":"https://stock-news.laohu8.com/highlight/detail?id=1106413707","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106413707?lang=en_us&edition=fundamental","pubTime":"2026-09-08 11:34","pubTimestamp":1788838468,"startTime":"0","endTime":"0","summary":"China Securities has released a research note indicating that the medical device sector maintained its revenue growth trajectory in Q2, with quarterly profit growth turning positive for the first...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0276","601066","GDOC","LGHT","PTH","RSPH","HART","IEIH","MDEV","BK1574","BK1583","BK1100","AGNG","MEDX","LNGR","09996","159883"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193693103","title":"European Equities Remain Flat as Energy Gains Offset by Pharma Slump","url":"https://stock-news.laohu8.com/highlight/detail?id=1193693103","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193693103?lang=en_us&edition=fundamental","pubTime":"2026-09-08 00:30","pubTimestamp":1788798644,"startTime":"0","endTime":"0","summary":"European markets closed Monday with little movement, as rising crude prices and a sharp decline in a major pharmaceutical firm counterbalanced each other. The benchmark Stoxx Europe 600 index...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OILU","SPDW","IFLR","DBE","GSIE","INTF","TLTD","GSEU","HAWX","MFSI","DMXU","BK4532","EFO","EPV","LU0070302665.USD","BK4504","RINT","WCMI","IEFA","JANI","EAFG","IDJN","IJUL","SEIE","DFAI","CVIE","IDME","GIEQ","AVSD","AVIV","ARLI","DRIP","IAUG","IDUB","NVS","XES","XLEX","TOK","ISEP","VEFA","AFDM","IXUS","QBIV","BBIN","DBEF","RDMX","FDT","AVNM","BK4550","ISWN","DUG","DFAX","VEA","BAIV","PGRI","JIRE","PEJ","NIHI","FDEV","WCMG","PQIN","XEUR","CGXU","BK4588","IE00BFTCPJ56.SGD","RODM","VDE","YMAR","IE0009355771.USD","DMXF","IOCT","URTH","IE00B4R5TH58.HKD","BK4570","MOTI","REFA","WTIU","QBIF","PIEQ","TDI","PIZ","JPIN","BINV","UPV","USOI","IVAL","BK4581","IMTM","IMAY","IFEB","OAIM","STXI","IBUF","ITOL","VEU","SDOG","VGK","SPXT","PZIV","APIE","BWET","BUFI","ESIM","FIEE","BK4007","BK4582","FLEE","IAPR","DWMF","FEOE","IDEQ","IMFL","ICOW","TPOR","PXJ","IDEV","IJAN","IDEC","FSZ","QLVD","TPIF","IQLT","IEO","IEV","IFV","VIDI","BRIE","JHMD","DIG","ILOW","KOKU","TOUS","IDMY","DRLL","RFEU","PPIE","FEDM","IE00BJT1NW94.SGD","IE00B2B36J28.USD","FFDI","BKIE","GSID","BBEU","EWN","FTXN","YSEP","BNO","SCHF","MEDX","NUDM","NBIE","OVF","DBC","PPH","TILC","PDEV","LU0208291251.USD","TACN","ACWX","RAYD","DBEU","JULI","HEFA","IMAR","DDWM","DFIC","QEFA","BUFY","IQDF","BK4167","FINT","OILK","RFDI","GXUS","USL","FEZ","DBO","DEEF","ICPY","OIH","IE00BJJMRZ35.SGD","TLCI","IGGY","WWJD","DXIV","IXC","GUSH","SPEU","IE0002141913.USD","VOOV","YDEC","RODE","LU0320765489.SGD","BKCI","FENI","IMOM","FEP","JDVI","XEML","GLOF","DINT","PTEU","INOV","VNIE","AIVI","FHIL","IJUN","UGA","XW","WEEI","IDMO","EFAX","PXF","IVSI","ENHI","CWI","AVDE","EUDG","ERX","ISDX","BK4020","EFZ","IEUR","PTIN","TXUE","EASG","OPPE","OILT","USE","CEFA","SSXU","BK4534","UIVM","OEFA","UAE","TIIV","DTAN","EPIN","EFA","PXE","EURL","BK4578","BK4585","CGIE","HFXI","GLBL","IQSI","MFDX","LU0211331839.USD","CGIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665317208","title":"Novartis AG Falls Monday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2665317208","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665317208?lang=en_us&edition=fundamental","pubTime":"2026-09-08 00:15","pubTimestamp":1788797700,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novartis AG  dropped 3.2% to CHF125.46 Monday on what proved to be an overall unfavorable trading session for the stock market, with the Swiss Market Index SMI Index  falling 0.8% to 14,279.38.Novartis AG closed CHF7.22 short of its 52-week high of CHF132.68, which the company achieved on September 3, 2026.Trading volume was 3,077,526, compared to the 50-day average trading volume of 2,290,037.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0208291251.USD","IE00B2B36J28.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4578","BK4585","NVS","IE00BJT1NW94.SGD","LU0320765489.SGD","IE0009355771.USD","LU0070302665.USD","MEDX","BK4532","PPH","BK4588","LU0211331839.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665176793","title":"Citi says Novartis news increases likelihood Crispr prioritizes next-gen CTX321","url":"https://stock-news.laohu8.com/highlight/detail?id=2665176793","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665176793?lang=en_us&edition=fundamental","pubTime":"2026-09-07 23:20","pubTimestamp":1788794419,"startTime":"0","endTime":"0","summary":"After Novartis (NVS) reported that pelacarsen’s Phase 3 HORIZON study failed to demonstrate a statistically significant reduction in major adverse ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citi-says-novartis-news-increases-likelihood-crispr-prioritizes-next-gen-ctx321-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citi-says-novartis-news-increases-likelihood-crispr-prioritizes-next-gen-ctx321-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJJMRZ35.SGD","NVS","MEDX","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0208291251.USD","BK4532","IE00BJT1NW94.SGD","LU0320765489.SGD","BK4585","LU0070302665.USD","LU0211331839.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","BK4588","IE0009355771.USD","PPH","BK4007","BK4578"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":16,"pageCount":14,"totalSize":302,"code":"91000000","status":"200"}]}}